Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Extension (LTE) Study of Mavacamten

Next Previous
X
Search
Trial Profile

A Long-Term Extension (LTE) Study of Mavacamten

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions; Registrational
  • Acronyms Mava-LTE
  • Sponsors MyoKardia

    • Most Recent Events

    • 17 May 2021 Interim Results (At data cutoff, n=137) evaluating long term safety of Mavacamten in patients with obstructive hypertrophic cardiomyopathy, presented at the 70th Annual Scientific Session of the American College of Cardiology
    • 24 Oct 2018 According to a MyoKardia media release, the patient dosing has been started in this study. Up to 280 patients who successfully complete either MAVERICK-HCM or EXPLORER-HCM clinical trials will be eligible for enrollment in this study.
    • 24 Oct 2018 Status changed from planning to recruiting, according to a MyoKardia media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top